Mumbai: India’s specialty manufacturing and healthcare firms have posted a mixed set of Q2 FY26 results — marked by topline volatility due to shipment delays and project phasing, but supported by resilient margins driven by cost control, improved product mix, and backward integration. Companies such as Blue Jet Healthcare, Indegene, and Sheela Foam are demonstrating how differentiated intellectual property, operating leverage, and portfolio premiumization can sustain profitability even in a tightening demand environment.
Blue Jet Healthcare: Temporary Dip, Structural Strength
Blue Jet Healthcare’s Q2 revenue declined 54% sequentially to ₹165 crore, primarily due to deferred shipments in its contrast media intermediates (CMI) segment. Despite the topline pressure, profitability remained strong — with EBITDA margin at 33% and PAT margin at 32%, supported by ₹24 crore in other income.
Management reiterated its medium-term EBITDA target of around 35%, emphasizing visibility across all verticals.
CMI: A 60-day shipment delay deferred approximately 45% of revenue recognition to Q3.
PI-API: H1 revenue rose 113% YoY to ₹255 crore, driven by supplies of bempedoic acid under long-term contracts.
Sweeteners: A key global customer approved a new molecule, making Blue Jet India’s sole supplier in this specialized niche.
The company’s aggressive capacity expansion plans — including a ₹300 crore backward integration project at Mahad and a ₹1,000 crore multi-block facility at Vizag — are expected to deliver margin-accretive growth from FY27 onwards.
Indegene: AI-Led Scale and Pharma-Tech Diversification
Digital pharma services major Indegene continued its double-digit growth trajectory, with Q1 FY26 revenue rising 17.1% YoY to ₹8,042 million, despite a 210 basis points margin dip attributed to wage hikes.
Its enterprise business — spanning content, analytics, and medical solutions — now contributes nearly 89% of total revenue, underscoring Indegene’s strategic pivot toward recurring, data-driven engagements with global pharmaceutical clients.
The company reported six new deal wins during the quarter, including two contracts with annual contract values (ACV) exceeding $3 million, reflecting strong traction in pharmacovigilance, medical operations, and GenAI-led automation.
Management expects mid-term margins to revert above 20%, aided by operational scaling, automation, and efficiency-enhancing productivity tools.
Sheela Foam: Premiumization and Retail Scale Powering Margins
Sheela Foam, the maker of Sleepwell and Kurlon, delivered steady growth in Q2 FY26, with revenue up 5% YoY to ₹1,696 crore and EBITDA margin remaining above 10%.
Mattress volumes rose 13%, the B2C mix increased to 55%, and synergy savings of ₹190 crore (with another ₹60 crore expected by Q3) are starting to reflect in profitability.
The company’s multi-channel expansion continues apace — adding 420 exclusive brand outlets (EBOs) in H1 (against a target of 800 for FY26) and launching 24 “Home Comfort” concept stores, reshaping its retail footprint across urban and semi-urban India.
Management has guided for 12–15% annual revenue growth with EBITDA margins expanding to 14–15% by FY28.
Its strategic investment in Furlenco, expected to surpass ₹500 crore in revenue by FY27, also provides an attractive retail-tech optionality, ahead of Furlenco’s planned IPO.
Broader Sector Outlook: Margins Over Momentum
The Q2 performance of India’s specialty manufacturing and healthcare names underscores a clear investor takeaway — margin sustainability now matters more than short-term revenue acceleration.
Companies with strong control over R&D, raw material sourcing, and brand mix are demonstrating superior resilience amid global demand uncertainty. As these firms embark on capex-heavy expansion plans, the second half of FY26 will test their execution discipline, but also offer an opportunity to translate deep order pipelines into scale-led earnings growth.
